WO2024201529 - FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST CHIKUNGUNYA VIRUS
National phase entry:
Publication Number
WO/2024/201529
Publication Date
03.10.2024
International Application No.
PCT/IN2024/050335
International Filing Date
29.03.2024
Title **
[English]
FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST CHIKUNGUNYA VIRUS
[French]
ANTICORPS MONOCLONAUX ENTIÈREMENT HUMAINS CONTRE LE VIRUS DU CHIKUNGUNYA
Applicants **
TECHINVENTION LIFECARE PRIVATE LIMITED
Inventors
AHMED, Kafil
PIDIYAR, Vyankatesh
AHMED, Syed
SYED, Safia
Priority Data
202221055910
29.03.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2021 | |
| EPO | Filing, Examination, Granting | 11130 | |
| Japan | Filing, Examination, Granting | 2086 | |
| South Korea | Filing, Examination, Granting | 1888 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,465
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to Bio-pharmaceuticals Specifically, the present invention relates to an isolated fully human monoclonal antibody or monoclonal antibody fragment or an immuno conjugate against Chikungunya. Further, the present invention relates to monoclonal antibodies against Chikungunya virus or an antigen-binding fragment of the monoclonal antibody, its composition and uses thereof. The present invention particularly relates to binding molecules against Chikungunya virus. The said monoclonal antibodies are capable of neutralizing Chikungunya virus infectivity. The present invention further relates to the use of monoclonal antibodies in the treatment or prevention or diagnosis of Chikungunya fever.[French]
La présente invention concerne des produits biopharmaceutiques. Plus particulièrement, la présente invention concerne un anticorps monoclonal entièrement humain isolé ou un fragment d'anticorps monoclonal ou un immunoconjugué contre le chikungunya. En outre, la présente invention concerne des anticorps monoclonaux contre le virus du chikungunya ou un fragment de liaison à l'antigène de l'anticorps monoclonal, sa composition et ses utilisations. La présente invention concerne en particulier des molécules de liaison contre le virus du chikungunya. Lesdits anticorps monoclonaux sont capables de neutraliser l'infectiosité du virus du chikungunya. La présente invention concerne en outre l'utilisation d'anticorps monoclonaux dans le traitement ou la prévention ou le diagnostic du chikungunya.